Status:
TERMINATED
Effects of 'R' (Electro-kinetic Beverage) on Insomnia, Fatigue, and Depression in Breast Cancer Patients Having Adjuvant Chemo
Lead Sponsor:
South Sound Care Foundation
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate the effects of consuming "R" on quality of life in the areas of insomnia, fatigue, and depression in female breast cancer patients receiving multi-cycle adjuva...
Detailed Description
Female breast cancer patients eligible for adjuvant therapy with four cycles of Taxotere and Cytoxan chemotherapy after surgery will be enrolled for the study. Eligible subjects will begin to consume...
Eligibility Criteria
Inclusion
- Female, non-smokers ≥ 18 years of age
- Histologically or cytologically confirmed diagnosis of Stage I or II adenocarcinoma of the breast and a candidate for adjuvant chemotherapy
- Scheduled to receive 4 cycles of adjuvant Taxotere and Cytoxan chemotherapy (TC): docetaxel 75 mg/m2 and cyclophosphamide 600 mg/m2 administered intravenously on Day 1 of each 21-day cycle
- Eastern Cooperative Oncology Group Status (ECOG) performance status of ≤ 1
- No prior treatment for breast cancer other than surgery
- Adequate baseline organ function as evidenced by:
- Hemoglobin ≥ 9 g/dL
- Absolute neutrophil count ≥ 1.5 x 109 cells/mm3
- Platelet count ≥ 100,000 cells/mm3
- Serum creatinine ≤ 1.5 x upper limit of normal (ULN)
- Alkaline phosphatase ≤ 1.5 x ULN
- No history of other malignancies within the last 5 years, except for carcinoma in situ of the cervix, or basal cell carcinoma or squamous cell carcinoma of the skin that have been previously treated with curative intent
- Women of childbearing potential who commit to using two forms of highly effective non-hormonal contraception either by the subject and/or partner during the study
- Negative urine pregnancy test at screening
- Negative urine drug screen (UDS) for drugs of abuse including cotinine (nicotine) at screening
- Subjects must be capable of understanding the purpose and risks of the study and provide written, voluntary informed consent
Exclusion
- Preexisting diagnosed psychiatric disorder as defined by The Diagnostic and Statistical Manual (DSM) of Mental Disorders (published by the American Psychiatric Association). Subjects with a diagnosis of depression will be allowed to enter into study as long as they have been treated with medication for ≥ 6 months and/or depression is considered to be well controlled
- Pregnant or lactating
- Diabetes
- Concomitant use of any sleeping agents during the course of the study (Anti- anxiety medications will be allowed)
- Steroid therapy other than the standard prescribed therapy of either of the following during the course of the study:
- Dexamethasone 4-12 mg IV on Day 1 of any cycle
- Dexamethasone 4-12 mg PO on Day 2 and Day 3 of any cycle
- Anti-estrogen therapy other than the standard prescribed therapy of one of the following:
- Tamoxifen/Nolvadex 20 mg PO daily
- Anastrazole/Arimidex 1 mg PO daily
- Letrozole/Femara 2.5 mg PO daily
- Exemestane/Aromasin 25 mg PO daily
- Use of any other antiemetic regimen other than the following (with the exception of PO antiemetics):
- Emend /Aprepitant150 mg IV on Day 1 of any cycle
- Aloxi/Palonosetron 0.25 mg IV on Day 1 of any cycle
- Dexamethasone 8 mg IV on Day 1 of any cycle
- Dexamethasone 8 mg PO on Day 2 and Day 3 of any cycle
- Zofran/Ondansetron 12 mg IV on Day 1 of any cycle
- Kytrile/Granisetron 1-2 mg IV on Day 1 of any cycle
- Therapy with any immunomodulatory or immunosuppressive drugs within 6 months prior to enrollment
- Known history of positive viral serology test for Human Immunodeficiency Virus (HIV-1), HBsAG and Hepatitis C antibody
- Any change in the initially prescribed chemotherapy
- Use of herbal remedies, dietary supplements or mega-vitamins, with the exception of a multi-vitamin
- Investigator deems the subject to be unable or unwilling to comply with the requirements of the protocol
Key Trial Info
Start Date :
January 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2016
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT02217033
Start Date
January 1 2013
End Date
April 1 2016
Last Update
April 18 2017
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
NWMS Bonney Lake - Medical Oncology
Bonney Lake, Washington, United States, 98391
2
NWMS Federal Way - Medical Oncology
Federal Way, Washington, United States, 98003
3
NWMS Gig Harbor - Medical Oncology
Gig Harbor, Washington, United States, 98332
4
NWMS Lakewood - Medical Oncology
Lakewood, Washington, United States, 98499